Novo Nordisk licenses Nanexa delivery tech in deal worth up to $1.33B to cut injection frequency for obesity and diabetes drugs

Novo Nordisk agreed to license and develop technology from Sweden's Nanexa that could make its obesity and diabetes drugs monthly or quarterly shots instead of frequent injections, in a deal worth up to $1.33B, the WSJ reports. The deal's financial terms were previously undisclosed.

Detected & updated continuously · Source: Nebula